Quantcast

Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference

April 11, 2011

FREISING, Germany, April 11, 2011 /PRNewswire/ — Pieris AG announced
today that Stephen Yoder, Chief Executive Officer, is scheduled to present at
the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference
2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel &
Conference Center in New York, New York. Mr. Yoder and Dr. Laurent Audoly,
Chief Scientific Officer, will be available to respond to questions during a
breakout session immediately following the presentation, and to participate
in one-on-one meetings.

Event: BioCentury Future Leaders in the Biotech Industry Conference 2011

Date: Friday, April 15, 2011

Time: 9:30 am ET (Breakout Session: 10:00-10:30 am ET)

Place: The Millennium Broadway Hotel & Conference Center, New York, NY
(Room 402/403)

Pieris AG is an independent, clinical-staged biotechnology company
advancing its proprietary Anticalin(r) technology to create safer, more
efficacious and more convenient protein therapeutics. Exclusive to Pieris,
Anticalin-based drugs promise to address high-unmet medical needs and expand
the therapeutic potential of current targeted approaches. Pieris’ pipeline
ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple
Anticalins in preclinical development. The company has three ongoing
collaborations: a drug discovery partnership with Takeda San Francisco; a
multi-year, multi-target agreement with Sanofi-Aventis and Sanofi Pasteur
(EUROMEXT: SAN and NYSE: SNY); and a deal with Allergan, Inc. (NYSE: AGN),
focusing on novel treatments for eye diseases. Privately held, Pieris has
been funded by premier biotechnology-focused venture capital, including lead
investors OrbiMed Advisors and Global Life Science Ventures. For more
information, please visit: http://www.pieris-ag.com.

    For more information, please contact:

    Stephen Yoder, CEO
    Pieris AG
    +49(0)8161-1411-400
    info@pieris-ag.com

SOURCE Pieris AG


Source: newswire



comments powered by Disqus